Clear cell adenocarcinoma is a rare type of cancer that gets its name from how the cells look under a microscope — they appear clear. This cancer most often starts in the female reproductive organs, especially the ovaries, uterus, cervix, or vagina. It can also occur in other parts of the body, but that is less common. Clear cell adenocarcinoma is a distinct disease from clear cell renal cell carcinoma, the most common form of kidney cancer. Understanding what this cancer is, where it develops, and how it is treated matters because early detection and proper care can improve outcomes.
What Is Clear Cell Adenocarcinoma?
Clear cell adenocarcinoma is a subtype of adenocarcinoma, which is a cancer that begins in glandular cells. The “clear cell” appearance comes from glycogen or other substances inside the cells that push the nucleus to the side, giving the cell a transparent look under a microscope. This cancer type is most frequently diagnosed in the ovaries, uterus (endometrium), cervix, and vagina. It accounts for about 5 to 10 percent of all ovarian cancers and a small percentage of endometrial cancers. In the cervix and vagina, it is very rare today because the main known cause — exposure to a drug called diethylstilbestrol (DES) during pregnancy — has been largely eliminated since the 1970s.
Where Does Clear Cell Adenocarcinoma Develop?
Clear cell adenocarcinoma can develop in several organs, but the most common sites are the female reproductive tract. Ovarian clear cell adenocarcinoma is often linked to endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus. Endometrial clear cell adenocarcinoma is a less common but more aggressive form of uterine cancer. Vaginal and cervical clear cell adenocarcinoma are strongly associated with in utero exposure to diethylstilbestrol (DES), a synthetic estrogen prescribed to pregnant women from the 1940s to the early 1970s to prevent miscarriage. Women whose mothers took DES during pregnancy have a higher risk of developing this cancer, usually after age 25. Clear cell adenocarcinoma can also occur in the bladder, kidneys, or other organs, but those are much rarer and often behave differently.
What Causes Clear Cell Adenocarcinoma?
The causes of clear cell adenocarcinoma vary by the organ involved. For ovarian clear cell adenocarcinoma, the strongest known risk factor is endometriosis. Research consistently shows that women with endometriosis have a higher chance of developing this specific ovarian cancer type. The exact biological link is not fully understood, but chronic inflammation and the presence of endometriosis lesions are thought to play a role. For vaginal and cervical clear cell adenocarcinoma, the clear cause is prenatal exposure to diethylstilbestrol (DES). This drug was banned for use in pregnancy in 1971, but women who were exposed in the womb remain at risk as they age. For endometrial clear cell adenocarcinoma, risk factors are similar to other endometrial cancers: older age, obesity, and possibly a history of tamoxifen use. However, clear cell endometrial cancer is not linked to estrogen exposure in the same way as the more common endometrioid type. It is important to note that clear cell adenocarcinoma of the cervix and vagina is not caused by the human papillomavirus (HPV), unlike most cervical cancers.
What Are the Symptoms of Clear Cell Adenocarcinoma?
Symptoms depend on where the cancer starts. Ovarian clear cell adenocarcinoma often causes no symptoms in early stages. When symptoms do appear, they can include bloating, pelvic pain, feeling full quickly, or changes in bowel or bladder habits. Endometrial clear cell adenocarcinoma typically causes abnormal vaginal bleeding, especially after menopause. Vaginal or cervical clear cell adenocarcinoma may cause abnormal bleeding or discharge, pain during intercourse, or pelvic pain. These symptoms are not specific to clear cell adenocarcinoma and can be caused by many other conditions. Any persistent or unusual symptoms should be evaluated by a doctor.
How Is Clear Cell Adenocarcinoma Diagnosed?
Diagnosis begins with a physical exam and imaging studies such as ultrasound, CT scan, or MRI. If a suspicious mass is found, a biopsy is needed to confirm the cancer type. The tissue sample is examined under a microscope by a pathologist who identifies the clear cells and other features. For ovarian masses, surgery is often the first step, and the diagnosis is made after the tumor is removed. For endometrial cancer, an endometrial biopsy or dilation and curettage (D&C) is used. For cervical or vaginal cancer, a colposcopy with biopsy is standard. Immunohistochemistry tests on the tissue can help distinguish clear cell adenocarcinoma from other cancers that have similar appearance.
What Are the Treatment Options for Clear Cell Adenocarcinoma?
Treatment depends on the stage, location, and the patient’s overall health. Surgery is the main treatment whenever possible. For ovarian clear cell adenocarcinoma, surgery includes removing the tumor, the ovaries and fallopian tubes, the uterus, and any visible cancer throughout the abdomen. For endometrial clear cell adenocarcinoma, a hysterectomy with removal of both ovaries and fallopian tubes is standard. After surgery, chemotherapy is often recommended. The most common chemotherapy regimen is a combination of carboplatin and paclitaxel. This is the same regimen used for other epithelial ovarian cancers. Some evidence suggests that clear cell adenocarcinoma may be less responsive to standard chemotherapy compared to other ovarian cancer types, but it remains the first-line treatment. Radiation therapy may be used for local control in endometrial, cervical, or vaginal clear cell adenocarcinoma, especially for advanced stage disease or if surgery is not possible. Targeted therapies and immunotherapies are being studied, but they are not yet standard of care for this specific cancer type.
What Is the Outlook for Clear Cell Adenocarcinoma?
The prognosis for clear cell adenocarcinoma depends heavily on the stage at diagnosis and the organ involved. Ovarian clear cell adenocarcinoma tends to be diagnosed at an earlier stage than the more common high-grade serous ovarian cancer because it often grows more slowly and causes symptoms earlier from the associated endometriosis. When diagnosed at stage I, the outlook is generally good. At advanced stages, the prognosis is poorer. Endometrial clear cell adenocarcinoma is considered a high-grade cancer and has a worse prognosis than the more common endometrioid type. Vaginal and cervical clear cell adenocarcinoma in DES-exposed women often has a better prognosis when detected early through regular screening. Overall, survival rates vary widely and are best determined by the patient’s own oncologist based on their specific situation.
Are There Screening Recommendations for Clear Cell Adenocarcinoma?
There are no routine screening tests for clear cell adenocarcinoma in the general population. Women who were exposed to DES in the womb are advised to have annual pelvic exams, Pap smears, and HPV testing starting at age 25, or earlier if symptoms occur. This is because the risk of clear cell adenocarcinoma of the vagina and cervix persists throughout life. For women with endometriosis, no specific screening is recommended beyond routine gynecologic care, but any new or worsening symptoms should be investigated promptly. There is no evidence that ultrasound or CA-125 blood testing reduces deaths from ovarian clear cell adenocarcinoma in women at average risk.
Frequently Asked Questions
Is clear cell adenocarcinoma the same as kidney cancer?
No. Clear cell adenocarcinoma of the ovary, uterus, cervix, or vagina is a different disease from clear cell renal cell carcinoma, which is the most common type of kidney cancer.
Can clear cell adenocarcinoma be cured?
Yes, when caught early and treated with surgery, many women are cured. For advanced stage disease, treatment can control the cancer for years but cure becomes less likely.
Does clear cell adenocarcinoma run in families?
Most cases are not inherited. However, some families with Lynch syndrome have an increased risk of endometrial cancer, which can include the clear cell subtype.
How common is clear cell adenocarcinoma in women exposed to DES?
The risk is low — about 1 in 1,000 DES-exposed women develops clear cell adenocarcinoma of the vagina or cervix. Regular screening is recommended to catch it early if it occurs.
